Corcept Therapeutics' (CORT) relacorilant combined with chemotherapy reduced death risk by 35% in platinum-resistant ovarian cancer patients, with FDA decision expected July 2026.
FDA issues Complete Response Letter for Corcept's relacorilant despite successful trials, requesting more evidence before approval for hypertension treatment in hypercortisolism patients.
The exclusive distributor for Corcept's drug Korlym quit after the company added a new pharmacy. This minor setback delays plans, but analysts advise buying the stock.
